Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07540221 Immune Globulin (Human)(Grifols) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540221 clinical trial report covering Immune Globulin (Human)(Grifols), Phase 3, endpoints, sponsor, geography, readout timing and development white s
Latest Hotspot
8 min read
NCT07540442 Comekibart Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540442 clinical trial report covering Comekibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122940 Omacetaxine Mepesuccinate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122940 clinical trial report covering Omacetaxine Mepesuccinate, Phase 3, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07539623 Suzetrigine Complications of bariatric procedures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539623 clinical trial report covering Suzetrigine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540364 Samelisant Cataplexy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540364 clinical trial report covering Samelisant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540390 Anlotinib Dihydrochloride Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540390 clinical trial report covering Anlotinib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123076 RB-0026 Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600123076 clinical trial report covering RB-0026, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07542483 Lebrikizumab Nummular eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07542483 clinical trial report covering Lebrikizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543380 RSVpreF Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543380 clinical trial report covering RSVpreF, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540988 Nerandomilast Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540988 clinical trial report covering Nerandomilast, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07541079 Giredestrant ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07541079 clinical trial report covering Giredestrant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07543224 RSS0393 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543224 clinical trial report covering RSS0393, Phase 3, endpoints, sponsor, geography, readout timing and development white space.